LSIPR 50 2017: Tim Haines
Name: Tim Haines
Organisation: Abingworth
Position: Managing partner
With more than 25 years of international management experience in the life sciences industry in both public and private companies, Tim Haines, managing partner of international investment group Abingworth, takes a spot in LSIPR 50.
Haines joined Abingworth in 2005, an investment company which has raised $375 million since 2010. The company was founded in 1973 and is dedicated exclusively to the life sciences and healthcare sectors.
One of the company’s more notable investments was in CRISPR Therapeutics, an early-stage biopharmaceutical company created to translate CRISPR-Cas9, the breakthrough gene-editing technology, into medicines. The company formed a collaboration with Vertex Pharmaceuticals, in a deal worth up to $2.6 billion
"The company was founded in 1973 and is dedicated exclusively to the life sciences and healthcare sectors."
Since Haines joined Abingworth, he has taken board roles in a number of companies including Astex, Fovea, Lombard Medical, Median Technologies, and Pixium Vision. Before joining Abingworth, he was CEO of Astex Therapeutics.
Abingworth is dedicated exclusively to the life sciences and healthcare sector and claims to have a lengthy track record of backing market-leading companies.
The firm has a specialist team of 26 professionals with a broad range of skillsets and access to an extensive network of industry contacts. It manages funds of more than $1.25 billion and has offices in London, Menlo Park (California) and Boston.
To date, Abingworth has raised 15 funds including ten venture funds dedicated to investment in life sciences and healthcare. Successful investments have included Ablynx, Algeta, Alkermes, Alnylam, Amarin, Astex, Avila Therapeutics, Chiasma, Clovis Oncology, Fovea, Geltex, Genetic Therapy, Gilead, IDEC Pharmaceuticals, Intellikine, Novexel, Pharmion, PowderMed and Solexa.
